drugset
drugset / Trial / NCT01330979

24-hour Efficacy of AR-12286

NCT01330979 ↗

Phase 2 Completed 5 enrolled Aerie Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

An open-label, non-comparative, pilot evaluation of the 24-hour ocular hypotensive efficacy of AR-12286 in patients with open-angle glaucoma or ocular hypertension

Timeline

Start
2011-05
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject VEROSUDIL Small molecule 0.5 % —

Indications

ocular hypertension open-angle glaucoma